INTS
INTENSITY THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$4.11
+5.93%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$4.31
From 52W high−87.55%
Volume45147.00
Market cap$13.42M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$4.31
From 52W high
−87.55%
Volume
45147.00
Market cap
$13.42M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.5x
P/E (TTM)
—
RSI (14)
36.8
MomentumView details →
1D Return
+5.93%
YTD Return
−62.82%
SummaryUpdated Jun 1, 2026
Intensity Therapeutics, Inc. (NASDAQ:INTS) is a clinical-stage biotechnology company founded in 2012 and headquartered in Westport, Connecticut. The company went public in June 2023 and focuses on developing innovative cancer treatments for solid tumors. Intensity Therapeutics operates in the oncology drug development space, with its lead product candidate currently in Phase 2 clinical trials for treating various refractory solid tumors including pancreatic, colon, bile duct, and other challenging cancers.
Similar companies
Latest newsMore news →